Figure 1: Agonist activity of anti-IgE antibodies of the invention in RBL-2H3 (FcεR1) cell assay.




Figure 2: Agonist activity of anti-IgE antibodies of the invention in RBL-2H3 (FcεR1) cell assay.




Figure 3: Agonist activity of anti-IgE antibodies of the invention in human blood basophil assay. Data are mean +/- SEM of 4 donors.




Figure 4: Agonist activity of anti-IgE antibodies of the invention in human blood basophil assay. Data are mean +/- SEM of 4 donors.




Figure 5: Epitope binning map

